China approves Sinopharm’s new coronavirus vaccine for clinical trials




A new Covid-19 vaccine developed by China’s Sinopharm has recently been approved for clinical trials.


The new recombinant Covid-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D centre of Sinopharm’s bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday, Xinhua reported.



The vaccine is based on the structural features of the receptor binding domain (RBD) on the virus’ spike protein (S-protein). It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralising antibodies.


The company said that recombinant vaccine technology is mature and suitable for large-scale production. The production does not require facilities with high biosafety levels since the process does not involve live viruses.


The recombinant vaccine is the company’s third Covid-19 vaccine. Last December, an inactivated vaccine developed by the Beijing Biological Products Institute Co., Ltd. under CNBG became the first Chinese Covid-19 vaccine to have conditional marketing authorisation.


In February, another inactivated vaccine from the Wuhan Institute of Biological Products, a CNBG affiliate, was allowed to enter the market on a conditional basis.


More than 161.12 million doses of Covid-19 vaccines had been administered across China as of Friday, the National Health Commission said on Saturday.


–IANS


gb/na

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *